These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 35781530)

  • 1. Engineering Antiviral Agents via Surface Plasmon Resonance.
    Maier I
    J Vis Exp; 2022 Jun; (184):. PubMed ID: 35781530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering recombinantly expressed lectin-based antiviral agents.
    Maier I
    Front Cell Infect Microbiol; 2022; 12():990875. PubMed ID: 36211961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
    Maier I; Schiestl RH; Kontaxis G
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34199200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyanovirin-N Binding to
    Maier I; Kontaxis G; Zimmermann C; Steininger C
    Biochemistry; 2024 May; 63(10):1270-1277. PubMed ID: 38770609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mannosylated hemagglutinin peptides bind cyanovirin-N independent of disulfide-bonds in complementary binding sites.
    Schilling PE; Kontaxis G; Dragosits M; Schiestl RH; Becker CFW; Maier I
    RSC Adv; 2020 Mar; 10(19):11079-11087. PubMed ID: 35495330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus.
    Barrientos LG; O'Keefe BR; Bray M; Sanchez A; Gronenborn AM; Boyd MR
    Antiviral Res; 2003 Mar; 58(1):47-56. PubMed ID: 12719006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein.
    Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T
    Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Designed "Nested" Dimer of Cyanovirin-N Increases Antiviral Activity.
    Woodrum BW; Maxwell J; Allen DM; Wilson J; Krumpe LR; Bobkov AA; Hill RB; Kibler KV; O'Keefe BR; Ghirlanda G
    Viruses; 2016 Jun; 8(6):. PubMed ID: 27275831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin.
    O'Keefe BR; Smee DF; Turpin JA; Saucedo CJ; Gustafson KR; Mori T; Blakeslee D; Buckheit R; Boyd MR
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2518-25. PubMed ID: 12878514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity.
    Fromme R; Katiliene Z; Giomarelli B; Bogani F; Mc Mahon J; Mori T; Fromme P; Ghirlanda G
    Biochemistry; 2007 Aug; 46(32):9199-207. PubMed ID: 17636873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120.
    Bewley CA; Otero-Quintero S
    J Am Chem Soc; 2001 May; 123(17):3892-902. PubMed ID: 11457139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivalent interactions with gp120 are required for the anti-HIV activity of Cyanovirin.
    Liu Y; Carroll JR; Holt LA; McMahon J; Giomarelli B; Ghirlanda G
    Biopolymers; 2009; 92(3):194-200. PubMed ID: 19235857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein.
    Kassa A; Dey AK; Sarkar P; Labranche C; Go EP; Clark DF; Sun Y; Nandi A; Hartog K; Desaire H; Montefiori D; Carfi A; Srivastava IK; Barnett SW
    PLoS One; 2013; 8(10):e76139. PubMed ID: 24146829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization.
    Matei E; Zheng A; Furey W; Rose J; Aiken C; Gronenborn AM
    J Biol Chem; 2010 Apr; 285(17):13057-65. PubMed ID: 20147291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins.
    Shenoy SR; O'Keefe BR; Bolmstedt AJ; Cartner LK; Boyd MR
    J Pharmacol Exp Ther; 2001 May; 297(2):704-10. PubMed ID: 11303061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure/Function Analysis of Truncated Amino-Terminal ACE2 Peptide Analogs That Bind to SARS-CoV-2 Spike Glycoprotein.
    Mackin RT; Edwards JV; Atuk EB; Beltrami N; Condon BD; Jayawickramarajah J; French AD
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants.
    Chang LC; Bewley CA
    J Mol Biol; 2002 Apr; 318(1):1-8. PubMed ID: 12054763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
    Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
    J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.
    Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R
    J Infect Dis; 2004 Apr; 189(8):1440-3. PubMed ID: 15073681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Homologous modeling and binding ability analysis of Spike protein after point mutation of severe acute respiratory syndrome coronavirus 2 to receptor proteins and potential antiviral drugs].
    Cao Z; Wang LT; Liu ZM
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 53(1):150-158. PubMed ID: 33550350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.